Palvella Therapeutics (PVLA) EBITDA (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of EBITDA data on file, last reported at -$14.9 million in Q1 2026.

• On a quarterly basis, EBITDA fell 88.73% year-over-year to -$14.9 million in Q1 2026; TTM through Mar 2026 was -$45.6 million, a 125.6% decrease from a year earlier, with the FY2025 full-year figure at -$38.6 million, down 173.87% from the prior year.
• EBITDA for Q1 2026 stood at -$14.9 million, down from -$11.3 million in the prior quarter.
• Over the last five years, EBITDA for PVLA reached as high as $13.4 million in Q4 2023 and fell as low as -$15.5 million in Q1 2023.
• Historically, EBITDA has averaged -$7.2 million across 5 years, with a median of -$9.2 million in 2025.
• Across the five-year window, EBITDA jumped 216.21% in 2023 and slumped 347.47% in 2025, its largest moves.
• Year by year, EBITDA stood at -$11.5 million in 2022, then soared by 216.21% to $13.4 million in 2023, then tumbled by 132.62% to -$4.4 million in 2024, then sank by 158.91% to -$11.3 million in 2025, then sank by 31.41% to -$14.9 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$14.9 million in Q1 2026, -$11.3 million in Q4 2025, and -$10.2 million in Q3 2025.